Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 17/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30013292 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL748096 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL750446 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL750207 | 0.99 | SLC6A4 (0.98) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL2788899 | 0.99 | SLC6A4 (0.98) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Isopropyl Alcohol SCHEMBL750603 | 0.93 | SLC6A4 (0.86) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Isopropyl Alcohol SCHEMBL747400 | 0.93 | SLC6A4 (0.86) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Cadaverine Tartrate SCHEMBL751056 | 0.91 | SLC6A4 (0.83) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Cadaverine Tartrate SCHEMBL16279185 | 0.91 | SLC6A4 (0.83) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL30014278 | 0.91 | SLC6A4 (0.84) | SLC6A4SLC6A2SLC6A3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | CONSYNANCE THERAPEUTICS INC (US) | 2023-03-16 | — | — | US | claimed |
| EP-4151210-A2 | PYRIDINE-CARBOLINE DERIVATIVES AS MCHR1 ANTAGONISTS FOR USE IN THERAPY | Harmony Biosciences, LLC (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | CONSYNANCE THERAPEUTICS INC (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230002377-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | HARMONY BIOSCIENCES MANAGEMENT, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20230002377-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | HARMONY BIOSCIENCES MANAGEMENT, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-2429296-B1 | 7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RES INC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2429296-B1 | 7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RES INC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2429296-B1 | 7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RES INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9604960-B2 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604960-B2 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| WO-2010132442-A1 | 7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RESERCH, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132442-A1 | 7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RESERCH, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132442-A1 | 7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RESERCH, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132437-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132437-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132487-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132487-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132487-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292250-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | MCHR1, MCHR2, MC1R | SLC6A4 79/4885SLC6A2 47/4885SLC6A3 37/4885 |
| US-20100292250-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | UACA, SCN1A, NLN | SLC6A4 389/4885SLC6A2 264/4885SLC6A3 716/4885 |
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | SLC6A4 98/4885SLC6A2 64/4885SLC6A3 87/4885 |
| US-20230002377-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | MCHR1, MCHR2, MC1R | SLC6A4 47/4885SLC6A2 23/4885SLC6A3 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.